Clinical Trials Currently Open

866-269-0309

Clinical Research Trials

Research Studies for Dermatologic Conditions

Advanced Dermatology and Cosmetic Surgery is a multi-state dermatology practice with more than 150+ locations nationwide. The Clinical Research Division was founded to find new and better ways to treat patients with dermatologic conditions through FDA-supervised clinical trials of leading-edge drugs, devices and other treatments.

New Clinical Research Studies

Males and Females, All Ages. Qualifying patients have or have had melanoma skin cancer.

We regularly seek participants for upcoming clinical research studies. If you are interested in being considered for future trials, you may submit your information to join our research interest list. When a study becomes available, our team may contact you if you meet the study criteria at a research location near you.

Current studies that are actively enrolling participants are listed below by location. If you do not see a study in your area, we encourage you to submit your interest to be considered for future opportunities.

Submit Your Interest

 

Study Details

Clinical research studies vary based on the condition being evaluated, treatment being studied, and study requirements. Past research studies have included areas such as skin cancer, eczema, psoriasis, hair loss, dermal fillers, and more.

The goal of each study is to gather and evaluate data related to patient demographics, treatment outcomes, safety, effectiveness, and other information associated with the treatment or approach being studied.

Study duration, eligibility criteria, compensation, and participation requirements vary by trial. Depending on the study, participation may involve office visits, treatment evaluations, questionnaires, or completion of study-related materials throughout the duration of the trial. Details and requirements will be provided for each study during the screening process.

 

Research Studies at Warren, Michigan

Grekin Skin Institute-Warren
​13450 E. 12 Mile Road
Warren, MI 48088

The following clinical trials, under the direction of Dr. Steven Grekin, are open and requesting participants who live in or near Warren or can travel here. Dr. Grekin, founder of The Grekin Skin Institute, has been involved in Clinical Research for drug and device development since 2002. He continues a family legacy of providing extraordinary dermatologic care and treatment which dates back through more than 100 years of physicians, including seven dermatologists.

Submit Your Interest

 

Plaque Psoriasis

Males and Females, Ages 18 to 80 years old. Qualifying patients will have moderate to severe plaque psoriasis.

Psoriasis is a chronic immune-mediated inflammatory disease with prominent skin manifestations that causes a substantial impact on quality of life.

 

Study Details

Grekin Skin Institute is enrolling adults for a double-blind, randomized, placebo treatment controlled study. The study will last 24 weeks with an 48-week follow up. There is no cost to participate, and insurance is not required. Qualified participants will be under the supervision of a board-certified dermatologist and receive up to $3,800 compensation for time and travel.

Compensation: up to $3,800 
Duration: 18 months
Visits: 15
 

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 18 and up. Qualifying patients will have moderate to severe atopic dermatitis (eczema). 

Atopic dermatitis, also known as eczema, is a chronic, inflammatory skin condition that's common in young children, but can occur at any age. It may cause itchiness, dry skin, rashes, scaly patches, thickening of the skin, blisters, and skin infections. This condition can weaken your skin’s barrier function, which helps your skin retain moisture and protects your body from outside elements. While there is no cure for eczema, dermatologists specialize in managing its symptoms through various treatments. 

 

Study Details

Grekin Skin Institute is enrolling adults in a double-blind, randomized, placebo treatment-controlled study. The study will last 12 weeks with a 4-week follow-up. There is no cost to participate, and insurance is not required. Qualified participants will be under the supervision of a board-certified dermatologist and receive up to $2,500 compensation for time and travel. 

An open label extension study may be available for subjects who qualify at the end of participation. 

Compensation: $2,500
Duration: 16 Weeks
Visits: 8

 

Research Studies at Spartanburg, South Carolina

Advanced Dermatology and Cosmetic Surgery
1650 Skylyn Dr, Ste 402
Spartanburg, SC 29307

Submit Your Interest

 

Generalized Pustular Psoriasis (GPP) 

Males and Females, Ages 18+ years old. Qualifying patients will have been diagnosed with Generalized Pustular Psoriasis (GPP).

GPP is a rare, severe form of pustular psoriasis. It is characterized by sudden widespread eruption of rash and sterile pustules with or without systemic inflammation and erythematous, painful skin. GPP can be associated with systemic inflammation including fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement.

 

Study Details

This is a prospective, observational registry that seeks to obtain information on the treatment patterns, and adverse events in a cohort of GPP patients. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 monts
Visits: 12

 

Alopecia Areata (Hair Loss)

Males and Females, Ages 18+ years old. Qualifying patients will have Alopecia Areata (AA) diagnosed at least 6 months ago and been prescribed a new medication within the past 12 months.

Alopecia Areata (AA) is an autoimmune disease that causes hair loss due to the immune system attacking hair follicles. It typically presents with discrete bald patches on the scalp but can affect all hair-bearing areas on the body. The exact cause is unclear, but it involves a loss of immune privilege in hair follicles, allowing autoantigens to be presented to autoreactive CD8+ T cells. Risk factors include certain susceptibility genes, family history of autoimmune disorders, and genetic makeup. 

 

Study Details

This is a prospective, observational registry study that seeks to create a cohort of AA patients to study the long-term safety and effectiveness of AA medications. Further, data collected will inform clinical decision making by patients and treating providers. This will be done through the standardized collection of validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns.

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 12

 

Alopecia Areata (Hair Loss)

Male and Female Adolescents, Ages 12 to 17 years old. Qualifying patients will have Alopecia Areata (AA).

Severe alopecia areata is an autoimmune disease that attacks the body’s hair follicles, causing patchy hair loss. While it doesn’t typically affect physical health, it can be mentally and emotionally challenging, especially adolescents already struggling with their changing self-identity and social expectations.   

 

Study Details

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss. This study begins with a double-blind, randomized, placebo-controlled Treatment Period of 24 weeks. It is a 4:1 placebo ratio. After 24 weeks, all subjects will receive Deuruxolitinib for 52 weeks. The study drug, study-related procedures, and study visits will be provided at no charge to you or your insurance company. 

Compensation: $100 per completed visit
Duration: Up to 84 weeks (about 1.5 years)
Visits: 18

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have diagnosed Atopic Dermatitis (AD) and prescribed to initiate a new systemic treatment for AD during their office visit at the Advanced Dermatology and Cosmetic Surgery location in Spartanburg.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. To qualify for this study, patients will be switched or initiated on a new systemic treatment (such as biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) by a qualified healthcare provider.

 

Study Details

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.

Compensation: $72-$80 per completed visit
Duration: Every 3-6 months, 60 months total
Visits: 13

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have moderate to severe atopic dermatitis (eczema) diagnosed at least 6 months ago. 

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. Lebrikizumab is a systemic, novel, subcutaneously injected IgG4 monoclonal antibody selectively targeting Interleukin-13 with high binding affinity and slow off-rate, as demonstrated by efficacy and safety in patients with moderate-to-severe AD in clinical studies.

 

Study Details

This is an observational study that seeks to understand the effects of lebrikizumab therapy on the treatment of pediatric and adult participants diagnosed with moderate-to-severe Atopic Dermatitis (AD). The research study will involve 8 study visits over the course of 24 months. Since this is an observational study, visits will align with routine care and subjects will only be required to fill out surveys and perform assessments during their visits.

Compensation: $672
Duration: 24 Weeks
Visits: 8

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12+. Qualifying patients will have moderate to severe atopic dermatitis (eczema) diagnosed at least 6 months ago. 

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life. 

 

Study Details

This prospective, multicenter, non-interventional study (NIS) seeks to evaluate treatment with nemolizumab of moderate-to-severe AD in adolescents and adults over an approximately 12-month period using physician assessments in routine clinical practice and PRO measures. Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. 

Compensation: $25 per visit
Duration: 12 Months
Visits: 5

 

Prurigo Nodularis (PN) 

Males and Females, Adults 18+. Qualifying patients will have a diagnosis of prurigo nodularis for at least 6 months prior to screening. 

Prurigo Nodularis is a chronic inflammatory skin disease that persistently causes intense itching and skin papules or nodules on certain areas of the skin – especially on arms, legs, or trunk. The disease at any age but is more commonly observed in middle-aged to elderly individuals and people with colored skin. Prurigo Nodularis is not contagious.

 

Study Details

This prospective, multicenter, non-interventional study (NIS) seeks to evaluate PN treatment with nemolizumab (Nemluvio®) in adults over an approximately 12-month period using physician assessments in routine clinical practice and PRO measures. Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice. 

Compensation: $25
Duration: 12 Months
Visits: 5

 

Research Studies at Denver, Colorado

Cara Mia Dermatology 
3540 S Poplar St, Ste 300
Denver, CO 80237

Submit Your Interest

 

Atopic Dermatitis

Males and Females, Ages 18+ years old. Qualifying patients will have a diagnosis of Atopic Dermatitis by a dermatologist or qualified dermatology provider and has been prescribed an eligible medication.

AD is a chronic skin condition that can cause dry, itchy patches, discoloration of the skin, and inflammation. This trial is evaluating an approved drug for adults whose AD has not improved with previous treatment.

 

Study Details

The objective of the CorEvitas Atopic Dermatitis (AD) Registry is to create a national cohort of patients with atopic dermatitis. Data collected will be used to extensively evaluate the effectiveness and safety of medications used to treat atopic dermatitis. This will be done through the standardized collection of patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), and the prevalence and incidence of comorbidities and adverse events, medication utilization patterns, and patient productivity measures.

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 12

 

Atopic Dermatitis (AD or Eczema)

Males and Females, Ages 18+ years old. Qualifying patients will have a diagnosis of Atopic Dermatitis by a dermatologist or qualified dermatology provider and has been prescribed an eligible medication.

AD is a chronic, relapsing inflammatory skin disease that significantly burdens the patient’s quality of life.

 

Study Details

This is a study of post approval drug safety and effectiveness with an optional biorepository. There will be no visits required outside of the patient’s standard of care.

Compensation: $25 per routine standard of care visit post enrollment in the study and $100 for the biorepository

 

 

Chronic Spontaneous Urticaria (Hives)

Males and Females, Ages 18+ years old. Qualifying patients will present with chronic spontaneous urticaria (hives).

Chronic urticaria is a condition characterized by the presence of hives, or wheals, on the skin that last for more than six weeks, often accompanied by itching and swelling. 

 

Study Details

This is a non-interventional prospective, multi-country, effectiveness and safety study to evaluate the treatment of chronic spontaneous urticaria.

Compensation: Up to $461
Duration: 2 years
 

 

Lichen Planopilaris (LPP)

Males and Females, Ages 18+ years old. Qualifying patients will present with a histologically confirmed diagnosis of lichen planopilaris (LPP).

LPP is an autoimmune inflammatory condition that causes scarring and permanent hair loss on the scalp by destroying hair follicles. It leads to symptoms such as redness and scale around hair follicles, itching, burning, tenderness, and bald patches.

 

Study Details

This is a phase 2/3 randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of oral investigational drug in adults with LPP. Enrolled subjects will participate in a 24-week blinded treatment period and then have the option to continue in an open label extension lasting an additional 24-weeks.

Compensation: Up to $1,125
Duration: Up to 56 weeks
Visits: 13

 

Research Studies at National Harbor, Maryland

Advanced Dermatology and Cosmetic Surgery
174 Waterfront St, Ste 200
National Harbor, MD 20745

Submit Your Interest

 

Alopecia Areata (Hair Loss)

Male and Female Adolescents, Ages 12 to 17 years old.  Qualifying patients will have a diagnosis of severe alopecia areata.  

Severe alopecia areata is an autoimmune disease that attacks the body’s hair follicles, causing patchy hair loss. While it doesn’t typically affect physical health, it can be mentally and emotionally challenging, especially adolescents already struggling with their changing self-identity and social expectations.  

 

Study Details

The objective of the registry is to create a cohort of adolescent subjects to evaluate the long-term real-world safety and effectiveness of routine clinical care treatments for severe AA. Data collected through the registry may be used to address a range of research questions and use cases including, but not limited to: better characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of severe AA in adolescents, providing information to support characterization of adolescent growth and development and ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs. 

Compensation: $25 per completed visit  
Frequency of visits: About every 6 months
 

 

Atopic Dermatitis (Eczema)

Males and Females, Ages 12 to 89. Qualifying patients will have been diagnosed with atopic dermatitis (eczema) and have had at least one eczema flare within the past 2 months. 

Atopic dermatitis (AD), also called eczema, is a skin condition associated with repeated periods of worsening symptoms known as flares. 

 

Study Details

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur. 

Compensation: Up to $1,140  
Duration: 3 months 
Visits: 5 visits

 

Research Studies at Henderson, Nevada

Advanced Dermatology and Cosmetic Surgery
861 Coronado Center Dr, Ste 100
Henderson, NV 89052

Submit Your Interest

 

Atopic Dermatitis (Eczema) 

Males and Females, Ages 12 to 89 years old.  Qualifying patients must have a clinical diagnosis of Atopic Dermatitis (Eczema) with at least one or more flare (as identified by the patient) in the past two months.  

Atopic Dermatitis, also known as Eczema, is a chronic, inflammatory skin condition with repeated periods of worsening symptoms known as flares. This condition can weaken your skin’s barrier function; researchers believe that changes in your skin’s barrier function may occur before visible skin changes or symptoms develop.

 

Study Details

This study will collect skin measurements from people with Atopic Dermatitis (Eczema) using the investigational Nevisense Go device. Participants will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin and aims to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Compensation: $975
Duration: 3 months
Visits: 5

 

Chronic Hand Eczema (CHE)  

Males and Females, Ages 18+ years old.  Qualifying patients will have a diagnosis of Chronic Hand Eczema by a dermatologist or qualified dermatology provider and has been prescribed an eligible medication.  

Chronic hand eczema (CHE) is a relapsing inflammatory disease of the hands defined by dermatitis that lasts at least 3 months or recurs two or more times within a year. It is common in working‑age adults.

 

Study Details

The objective of the registry is to create a cohort of CHE subjects to evaluate long-term real-world safety and effectiveness of standard of care treatments for CHE. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of CHE, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs.   

Compensation: $25 per completed visit
Duration: Every 6 months
Visits: 6

 

Non-Segmental Vitiligo (NSV)

Males and Females, Ages 18+ years old. Qualifying patients will have a diagnosis of Non-Segmental Vitiligo by a dermatologist or qualified dermatology provider and has been prescribed an eligible medication.  

Vitiligo is a chronic, immune-mediated disorder of the skin characterized by progressive loss of functional melanocytes, leading to well-demarcated depigmented macules and patches. Although the underlying biological process remains unclear, multiple factors contribute to disease development, including genetic and environmental factors as well as others.   

 

Study Details

The objective of the registry is to create a cohort of adult and adolescent nonsegmental vitiligo (NSV) subjects to evaluate long-term real-world safety and effectiveness of standard of care treatments for NSV. Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of NSV, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs. 

Compensation: $25 per completed visit
Duration: About every 6 months
 

 

In the News

In the past, our clinical study results indicated that more than one million skin cancers went undiagnosed in 2020 as a result of COVID-19 concerns, and that total-body skin cancer exams are the most effective way to find skin cancers were published nationally in the January 19, 2021 edition of the Journal of the American Academy of Dermatology (JAAD) and Journal of Clinical Oncology®, an American Society of Clinical Oncology (ASCO) Journal.

 

About Us

What We Do, Our Mission, and Research Investigators

LEARN MORE

 

 

Sponsors and CROs

Reasons to Partner With Us on Clinical Trials

LEARN MORE

 

Lichen Planopilaris (LPP)

Males and Females, Ages 18+ years old. Qualifying patients will present with a histologically confirmed diagnosis of lichen planopilaris (LPP).

LPP is an autoimmune inflammatory condition that causes scarring and permanent hair loss on the scalp by destroying hair follicles. It leads to symptoms such as redness and scale around hair follicles, itching, burning, tenderness, and bald patches.

 

Study Details

This is a phase 2/3 randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of oral investigational drug in adults with LPP. Enrolled subjects will participate in a 24-week blinded treatment period and then have the option to continue in an open label extension lasting an additional 24-weeks.

Compensation: Up to $1,125
Duration: Up to 56 weeks
Visits: 13

 

Locations

Advanced Dermatology and
Cosmetic Surgery
1650 Skylyn Dr, Ste 402
Spartanburg, SC 29307

Spartanburg, SC
Amylynne Frankel, MD, FAAD
Principal Investigator

Grekin Skin Institute
Part of Advanced Dermatology and Cosmetic Surgery
13450 E. 12 Mile Rd.
Warren, Michigan 48088

Warren, MI
Steve Grekin, DO
Principal Investigator

Grekin Skin Institute
Part of Advanced Dermatology and Cosmetic Surgery
13450 E. 12 Mile Rd.
Warren, Michigan 48088

Dr. Jeremy Grekin

Warren, MI
Jeremy Grekin, MD
Principal Investigator

 

Advanced Dermatology and Cosmetic Surgery
861 Coronado Center Dr, Ste 100
Henderson, NV 89052

Dr. Grace Kim

Henderson, NV
Grace (Dowty) Kim, DO
Principal Investigator

 

​Advanced Dermatology and Cosmetic Surgery
600 W Plymouth Ave
Deland, FL 32720

Dr. Charlie Dunn

Deland, FL
Charlie Dunn, MD
Principal Investigator

 

Cara Mia Dermatology 

3540 S Poplar St, Ste 300
Denver, CO 80237

Dr. Elizabeth Robinson

Denver, CO
Elizabeth Robinson, MD
Principal Investigator

Added to Cart​

Checkout​

Images are loading, please wailt a minute.

Thank you for reaching out. Our staff will contact you within 24 hours!
Cannot submit your request. Please try again later
close popup